NASDAQ:TRVI • US89532M1018
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for TREVI THERAPEUTICS INC (TRVI).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-19 | Jones Trading | Maintains | Buy -> Buy |
| 2026-03-18 | D. Boral Capital | Maintains | Buy -> Buy |
| 2026-03-18 | Needham | Maintains | Buy -> Buy |
| 2026-03-18 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2026-03-09 | D. Boral Capital | Maintains | Buy -> Buy |
| 2026-03-09 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2026-01-09 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2026-01-08 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-12-19 | Stifel | Maintains | Buy -> Buy |
| 2025-11-20 | Leerink Partners | Maintains | Outperform -> Outperform |
| 2025-11-14 | Clear Street | Maintains | Buy -> Buy |
| 2025-11-14 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-11-14 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-11-14 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-08-21 | Morgan Stanley | Initiate | Overweight |
| 2025-08-08 | Needham | Maintains | Buy -> Buy |
| 2025-08-08 | Raymond James | Maintains | Strong Buy -> Strong Buy |
| 2025-07-01 | Cantor Fitzgerald | Initiate | Overweight |
| 2025-06-02 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-05-28 | HC Wainwright & Co. | Initiate | Buy |
| 2025-05-20 | Needham | Reiterate | Buy -> Buy |
| 2025-04-08 | Needham | Reiterate | Buy -> Buy |
| 2025-03-19 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-03-19 | Needham | Maintains | Buy -> Buy |
| 2025-03-19 | B. Riley Securities | Reiterate | Buy -> Buy |
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A 623.65% | N/A 152.87% | N/A 53.73% | N/A 60.68% | N/A 40.20% | |||||||||||
| EBITDA YoY % growth | -8.63M | -8.24M 4.52% | -18.39M -123.18% | -26.61M -44.70% | -32.44M -21.91% | -32.43M 0.03% | -29.87M 7.89% | -33.8M -13.16% | -51.377M -52.00% | -49.184M 4.27% | N/A -51.83% | N/A -25.07% | N/A -43.56% | N/A -12.32% | N/A 101.35% | N/A 16,874.91% | N/A 149.71% | N/A 57.24% | |
| EBIT YoY % growth | -8.63M | -8.24M 4.52% | -18.41M -123.42% | -26.65M -44.76% | -32.49M -21.91% | -32.48M 0.03% | -29.91M 7.91% | -33.923M -13.42% | -51.524M -51.89% | -49.328M 4.26% | N/A -48.08% | N/A -35.29% | N/A 28.45% | N/A 91.46% | N/A 5,134.30% | N/A 72.26% | N/A 83.90% | N/A 49.43% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | N/A | -1.81 9.58% | -1.52 16.02% | -0.56 63.16% | -0.29 48.21% | -0.47 -62.07% | -0.32 31.91% | N/A -43.49% | N/A -34.10% | N/A -23.76% | N/A 83.55% | N/A 1,020.59% | N/A 154.40% | N/A 50.03% | N/A 33.58% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.08 13.30% | -0.10 -16.08% | -0.13 -60.97% | -0.15 -142.11% |
| Revenue Q2Q % growth | ||||
| EBITDA Q2Q % growth | -15.562M -36.12% | -18.599M -36.28% | -21.228M -53.79% | -22.49M -123.20% |
| EBIT Q2Q % growth | -12.561M -9.52% | -15.966M -16.35% | -19.783M -42.16% | -22.206M -117.28% |
All data in USD
18 analysts have analysed TRVI and the average price target is 21.93 USD. This implies a price increase of 55.86% is expected in the next year compared to the current price of 14.07.
TREVI THERAPEUTICS INC (TRVI) will report earnings on 2026-05-07.
The consensus EPS estimate for the next earnings of TREVI THERAPEUTICS INC (TRVI) is -0.08 USD and the consensus revenue estimate is 0 USD.
The consensus rating for TREVI THERAPEUTICS INC (TRVI) is 85.5556 / 100 . This indicates that analysts generally have a positive outlook on the stock.